Congenital adrenal hyperplasia: Difference between revisions

Jump to navigation Jump to search
No edit summary
(Undo revision 1465293 by Mehrian.jafari (talk))
 
(147 intermediate revisions by 7 users not shown)
Line 1: Line 1:
'''This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on [[21-hydroxylase deficiency]], [[17 alpha-hydroxylase deficiency]], [[11β-hydroxylase deficiency]], [[3 beta-hydroxysteroid dehydrogenase deficiency]], [[cytochrome P450-oxidoreductase (POR) deficiency (ORD)]], [[congenital lipoid adrenal hyperplasia]]'''.
<div style="-webkit-user-select: none;">
__NOTOC__
__NOTOC__
{{SI}}
{{Infobox Disease
{{CMG}}; {{AE}} {{CZ}}; {{Ammu}}
| Name = Adrenal insufficiency
| Image = Illu adrenal gland.jpg
| Caption = Adrenal gland
}}
{{Congenital adrenal hyperplasia}}


{{SK}} CAH; Adrenogenital syndrome
{{CMG}}; {{AE}}{{MJ}}
 
{{SK}} Congenital adrenal hyperplasia; CAH; Adrenal hyperplasia.


==Overview==
==Overview==
Congenital adrenal hyperplasia is a group of [[autosome|autosomal]] [[recessive]] [[disease]]s that result from multiple [[genetic]] mutations. The genes encode a number of enzymes that mediate the adrenal glands [[steroidogenesis]] pathway. As a result, mutations in such genes will result in various enzyme deficiencies that lead to a disequilibrium of the biochemical reactions mediating the production of cortisol, aldesterone, and androgens.<ref name="Warrell2005">{{cite book|author=David A. Warrell|title=Oxford textbook of medicine: Sections 18-33|url=https://books.google.com/books?id=hL1NKQJlY1IC&pg=PA261|accessdate=14 June 2010|year=2005|publisher=Oxford University Press|isbn=978-0-19-856978-7|pages=261–}}</ref> The outcome of congenital adrenal hyperplasia is either an excessive or deficient production of the aforementioned hormones, which alters the development of both [[primary sex characteristic|primary]] and [[secondary sex characteristic]]s among affected patients.<ref name="MilunskyMilunsky2010">{{cite book|author1=Aubrey Milunsky|author2=Jeff Milunsky|title=Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment|url=https://books.google.com/books?id=oKCmA4dOYtMC&pg=PA600|accessdate=14 June 2010|date=29 January 2010|publisher=John Wiley and Sons|isbn=978-1-4051-9087-9|pages=600–}}</ref> Congenital adrenal hyperplasia may be classified according to
Congenital adrenal hyperplasia consists of several disorders resulting from defective [[enzymes]] and [[proteins]] involved in [[steroid]] and [[cortisol]] synthesis pathways. Defects in [[steroid]] [[biosynthesis]] are caused by several [[genetic mutations]] and may lead to [[delayed puberty]], [[precocious puberty]] or [[ambiguous genitalia]] in specific disorders. The decrease in [[cortisol]] level leads to the release of the inhibitory feedback on [[corticotropin]] ([[ACTH]]) production. The high [[ACTH]] level causes increase [[cortisol]] precursors and overproduction of other [[hormones]]. The most common cause of congenital adrenal hyperplasia is a [[21-hydroxylase deficiency]], which accounts for more than 95% of cases. Other causes include [[17 alpha-hydroxylase deficiency]], [[11β-hydroxylase deficiency]], [[3 beta-hydroxysteroid dehydrogenase deficiency]], [[Cytochrome P450-oxidoreductase (POR) deficiency (ORD)]], and [[congenital lipoid adrenal hyperplasia]].
biochemical enzyme deficiency into commonly five subtypes: [[lipoid congenital adrenal hyperplasia]], [[congenital adrenal hyperplasia due to 21-hydroxylase deficiency]], [[congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency]], [[congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency]], and [[congenital adrenal hyperplasia due to 11β-hydroxylase deficiency]].
 
===Congenital Adrenal Hyperplasia===
==Classification==
* The figure below illustrates the biochemical reactions of the adrenal glands [[steroidogenesis]] pathway:
Congenital adrenal hyperplasia (CAH) is classified into seven types based on the [[genetic]] causes that lead to [[hyperplasia]] and [[Hormone|hormonal]] imbalance. CAH is [[hyperplasia]] of different layer of [[Adrenal cortex]]. Within the [[adrenal cortex]], there are three layers named zones; each of them has a distinct cell type and secrete specific [[hormones]].  
<br>
==== [[Adrenal cortex]] zones based on the hormonal synthesis ability and location: ====
[[Image:DHEA1_svg.png|thumb|center|800px|Production of DHEA from Cholesterol. ([[Cortisol]] is a [[glucocorticoid]].)]]
<div style="-webkit-user-select: none;">
* Zona glumerulosa:
** The outer layer of [[adrenal cortex|adrenal cortex.]]
** Laying directly under the [[Adrenal gland|adrenal]] [[capsule]].
** Secretion: [[Aldosterone]] synthesis.
* Zona fasciculate:
** The middle part of [[adrenal cortex]]
** Laying under zona glumerulosa
** Secretion: [[Cortisol]] synthesis
* Zona reticularis:
** The inner part of [[adrenal cortex]]
** Laying between zona fasciculate and [[adrenal medulla]]
** Secretion: [[Androgen]] synthesis
 
[[image:Adrenal cortex labelled.jpg|600px|center|thumb|[[Adrenal cortex]] zones -  By Jpogi - https://commons.wikimedia.org/wiki/File:Adrenal_gland_%28cortex%29.JPG, CC0, https://commons.wikimedia.org/w/index.php?curid=37838551]]


==Historical Perspective==
==== Impairment of each pathway and [[enzyme]] may lead to a specific subtype of congenital adrenal hyperplasia include: ====
<div style="-webkit-user-select: none;">
* [[21-hydroxylase deficiency]]
* [[17 alpha-hydroxylase deficiency]]
* [[11β-hydroxylase deficiency]]
* [[3 beta-hydroxysteroid dehydrogenase deficiency]]
* [[Cytochrome P450-oxidoreductase (POR) deficiency (ORD)]]
* [[Congenital lipoid adrenal hyperplasia]]
 
====Adrenal steroid synthesis pathways in adrenal cortex and related enzymes====
 
[[image:Adrenal Steroids.png|thumb|800px|center|Adrenal steroid synthesis pathways in adrenal cortex and related enzymes <ref name="urlFile:Adrenal Steroids Pathways.svg - Wikimedia Commons">{{cite web |url=https://commons.wikimedia.org/wiki/File:Adrenal_Steroids_Pathways.svg|title=File:Adrenal Steroids Pathways.svg - Wikimedia Commons |format= |work= |accessdate=}}</ref>]]
 
==== Summary and important Characteristics of the different congenital adrenal hyperplasia subtypes: <ref name="pmid2164530">{{cite journal |vauthors=Moreira AC, Leal AM, Castro M |title=Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency |journal=J. Clin. Endocrinol. Metab. |volume=71 |issue=1 |pages=86–91 |year=1990 |pmid=2164530 |doi=10.1210/jcem-71-1-86 |url=}}</ref><ref name="pmid999330">{{cite journal |vauthors=Heremans GF, Moolenaar AJ, van Gelderen HH |title=Female phenotype in a male child due to 17-alpha-hydroxylase deficiency |journal=Arch. Dis. Child. |volume=51 |issue=9 |pages=721–3 |year=1976 |pmid=999330 |pmc=1546244 |doi= |url=}}</ref><ref name="pmid226795">{{cite journal |vauthors=Biglieri EG |title=Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome |journal=J. Steroid Biochem. |volume=11 |issue=1B |pages=653–7 |year=1979 |pmid=226795 |doi= |url=}}</ref>====
<div style="-webkit-user-select: none;">
{| class="wikitable" align="center" style="border: 0px; font-size: 90%; margin: 3px;"
! colspan="2" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History and symptoms
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory findings
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Defective gene
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Blood pressure
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Genitalia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Cortisol
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Aldosterone
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Androgens
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Estrogens
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Increased hormone precursors
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Potassium levels
|-
| rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[21-hydroxylase deficiency]]
| style="background:#DCDCDC;" |Classic type, salt-wasting
| align="center" style="padding: 5px 5px; background: " |↓
|
* Female: [[Ambiguous genitalia]]
 
* Male: Normal or scrotal [[pigmentation]] and large phallus 
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓↓
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |Relatively low
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
| align="center" style="padding: 5px 5px; background: " |↑
|
[[CYP21A1]] and [[CYP21A2]] gene
|-
| style="background:#DCDCDC;" |Classic type, non-salt-wasting
| align="center" style="padding: 5px 5px; background: " |Normal
|
* Female: [[Ambiguous genitalia]]
 
* Male: normal or scrotal pigmentation and large phallus
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |Relatively low
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
| align="center" style="padding: 5px 5px; background: " |Normal
|[[CYP21A1]] and [[CYP21A2]] gene
|-
| style="background:#DCDCDC;" |Non-classic type
| align="center" style="padding: 5px 5px; background: " |Normal
|
* Female: [[Virilization]] after [[puberty]]
* Male: Normal appearance
| align="center" style="padding: 5px 5px; background: " |Normal
| align="center" style="padding: 5px 5px; background: " |Normal
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |Relatively low
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* Exaggerated [[Androstenedione]], [[DHEA]], and [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] response to [[ACTH]]
| align="center" style="padding: 5px 5px; background: " |Normal
|
[[CYP21A1]] and [[CYP21A2]] gene
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: " |↑
|
* Female: Normal
* Male: [[Ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: " |Normal [[corticosterone]]
Normal [[cortisol]]
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
|
* [[Deoxycorticosterone]]
* [[Progesterone]]
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |[[CYP17A1]]
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: " |↑
|
* Female: [[Ambiguous genitalia]]
 
* Male: Normal or scrotal pigmentation and large [[Phallus (embryology)|phallus]]
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |Relatively low
|
* [[Deoxycorticosterone]]
* 11-Deoxy-[[cortisol]]
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]], mild elevation
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |CYP11B1
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[3 beta-hydroxysteroid dehydrogenase deficiency]]
| align="center" style="padding: 5px 5px; background: " |↓
|
* Both male and female: [[Ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |Male:↓
Female:↑
| align="center" style="padding: 5px 5px; background: " |↓
|
* [[Dehydroepiandrosterone]]
* [[17-hydroxypregnenolone]]
* [[Pregnenolone]]
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |HSD3B2
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Cytochrome P450-oxidoreductase (POR) deficiency (ORD)]]
| align="center" style="padding: 5px 5px; background: " |Normal
|
* Both male and female: [[Ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: " |↓


==Classification==
| align="center" style="padding: 5px 5px; background: " |Normal
* Congenital adrenal hyperplasia may be classified according to biochemical enzyme deficiency into commonly the following types:
| align="center" style="padding: 5px 5px; background: " |
<br>
| align="center" style="padding: 5px 5px; background: " |↓
{{Familytree/start}}
|
{{Familytree|boxstyle=background: #E0FFFF;| | | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | |A01=<div style="width: 20em; padding:0.5em;">'''Congenital Adrenal Hyperplasia'''</div>}}
* [[Dehydroepiandrosterone]]
{{Familytree|boxstyle=background: #E0FFFF;| | | | |,|-|-|-|-|v|-|-|-|-|+|-|-|-|-|v|-|-|-|-|.| | | | | | | | | | | | | |}}
* [[17-hydroxypregnenolone]]
{{Familytree|boxstyle=background: #E0FFFF;| | | | B01 | | | B02 | | | B03 | | | B04 | | | B05 | | | | | | | | | | | |B01= <div style="width: 15em; padding:0.5em;">[[Lipoid congenital adrenal hyperplasia]]</div>|B02= <div style="width: 15em; padding:0.5em;">[[Congenital adrenal hyperplasia due to 21-hydroxylase deficiency]]</div>|B03= <div style="width: 15em; padding:0.5em;"> [[Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency]]</div>|B04= <div style="width: 15em; padding:0.5em;"> [[Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency]] </div>|B05= <div style="width: 15em; padding:0.5em;"> [[Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency]] </div>}}
* [[Pregnenolone]]
{{Familytree/end}}
| align="center" style="padding: 5px 5px; background: " |Normal
<br>
|[[Mutations]] in the [[flavoprotein]] co-factor of the enzymes [[CYP17A1]], [[CYP21A2]], and [[CYP19A1]] ([[aromatase]]).
===Biochemistry===
|-
* The table below lists the specific biochemical abnormalities present among the different types of congenital adrenal hyperplasia:
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Congenital lipoid adrenal hyperplasia]]
<br>
| align="center" style="padding: 5px 5px; background: " |↓
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px"
|
|valign=top|
* Female: Normal, [[delayed puberty]] in females
|+
* Male: [[Ambiguous genitalia]]
! style="background: #4479BA; width: 200px; color: #FFFFFF;"|'''Common Medical Term'''
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |None of precursors increased
| align="center" style="padding: 5px 5px; background: " |
|[[Gene mutation|Gene mutations]] on [[Chromosome 8 (human)|chromosome 8]], codes for a [[protein]] called [[steroid]] acute regulatory protein (StAR)
|}


! style="background: #4479BA; width: 600px; color: #FFFFFF;"|'''OMIM Number'''
==Differential Diagnosis==
Congenital adrenal hyperplasia can present with different symptoms such as:
* [[Ambiguous genitalia]]
* [[Virilization]] and [[hirsutism]] in female
* [[Primary amenorrhea]]
* Low reninemic [[hypertension]]
Differential diagnosis for each of these symptoms are described in below tables.


! style="background: #4479BA; width: 200px; color: #FFFFFF;"|'''Enzyme'''
===[[Congenital adrenal hyperplasia]] must be differentiated from diseases that cause [[ambiguous genitalia]]:<ref name="pmid17875484">{{cite journal |vauthors=Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT |title=Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development |journal=Best Pract. Res. Clin. Endocrinol. Metab. |volume=21 |issue=3 |pages=351–65 |year=2007 |pmid=17875484 |doi=10.1016/j.beem.2007.06.003 |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref>===


! style="background: #4479BA; width: 200px; color: #FFFFFF;"|'''Gene location'''
{| class="wikitable"
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Steroid status
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Increased
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Decreased
|-
|[[21-hydroxylase deficiency|Classic type of 21-hydroxylase deficiency]]
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* [[Progesterone]]
* [[Androstenedione]]
* [[DHEA]]
|
* [[Aldosterone]]
* [[Corticosterone]] (salt-wasting)
* [[Cortisol]] ([[virilization]])
|
* [[Ambiguous genitalia]] in female
* [[Virilization]] in female
* Salt-wasting
* [[Hypotension]] and [[hyperkalemia]]
|-
|[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
|
* [[Deoxycorticosterone]]
* 11-Deoxy-[[cortisol]]
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] (mild elevation)
|
* [[Cortisol]]
* [[Corticosterone]]
* [[Aldosterone]]
|
* [[Ambiguous genitalia]] in female
* [[Hypertension]] and [[hypokalemia]]
* [[Virilization]]
|-
|[[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]]
|
* [[Deoxycorticosterone]]
* [[Corticosterone]]
* [[Progesterone]]
|
* [[Cortisol]]
* [[Aldosterone]]
|
* [[Ambiguous genitalia]] in male
* [[Hypertension]]


! style="background: #4479BA; width: 600px; color: #FFFFFF;"|'''Substrates'''
* [[Primary amenorrhea]]


! style="background: #4479BA; width: 600px; color: #FFFFFF;"|'''Products'''
* Absence of [[secondary sexual characteristics]]


* Minimal [[body hair]]
|-
|-
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
|
* [[Dehydroepiandrosterone]]
* [[17-hydroxypregnenolone]]
* [[Pregnenolone]]
|
* [[Cortisol]]
* [[Aldosterone]]
|
* [[Vomiting]], [[volume depletion]], [[hyponatremia]], and [[hyperkalemia]]
* 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis
|-
| Gestational [[hyperandrogenism]]
| colspan="2" |
* Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high
* If [[virilization]] is caused by exogenous [[hormone]] administration, the values may be low because the offending hormone is usually a synthetic [[steroid]] not measured in assays for [[testosterone]] or other [[androgens]]
|
* [[Androgen]] excess in mother
* History of [[androgen]] containing [[medication]]  consumption during [[pregnancy]] in mother
* [[Virilization]] in a 46,XX individual with normal female internal anatomy
* Causes include maternal [[luteoma]] or theca-[[lutein]] [[cysts]], and [[placental]] [[aromatase]] enzyme deficiency
|}


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |
===Congenital adrenal hyperplasia must be differentiated from diseases that cause [[virilization]] and [[hirsutism]] in female:<ref name="pmid24830586">{{cite journal |vauthors=Hohl A, Ronsoni MF, Oliveira Md |title=Hirsutism: diagnosis and treatment |journal=Arq Bras Endocrinol Metabol |volume=58 |issue=2 |pages=97–107 |year=2014 |pmid=24830586 |doi= |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref><ref name="ISBN:978-0323297387">{{cite book | last = Melmed | first = Shlomo | title = Williams textbook of endocrinology | publisher = Elsevier | location = Philadelphia, PA | year = 2016 | isbn = 978-0323297387 }}=</ref>===
''' [[Congenital adrenal hyperplasia due to 21-hydroxylase deficiency|21-hydroxylase CAH]]'''
| style="padding: 5px 5px; background: #F5F5F5;"|
:{{OMIM|201910}}  
| style="padding: 5px 5px; background: #F5F5F5;"|  
:P450c21
| style="padding: 5px 5px; background: #F5F5F5;"|
:6p21.3
| style="padding: 5px 5px; background: #F5F5F5;"|  
:17OH-progesterone→ <br/>[[Progesterone]] 
| style="padding: 5px 5px; background: #F5F5F5;"|  
:11-deoxycortisol→<br/>[[11-deoxycorticosterone|DOC]]


{| class="wikitable"
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Steroid status
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other laboratory
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings
|-
|-
|Non-classic type of [[21-hydroxylase deficiency]]
|Increased:
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* Exaggerated [[Androstenedione]], [[DHEA]], and [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] in response to [[ACTH]]
|
* Low [[testosterone]] levels
|
* No symptoms in infancy and male


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |
* [[Virilization]] in females
''' [[Lipoid congenital adrenal hyperplasia|lipoid CAH]]<br/>(20,22-desmolase)'''
| style="padding: 5px 5px; background: #F5F5F5;"|
:{{OMIM|201710}}
| style="padding: 5px 5px; background: #F5F5F5;"|
:StAR<br/>P450scc
| style="padding: 5px 5px; background: #F5F5F5;"|
:8p11.2<br/>15q23-q24
| style="padding: 5px 5px; background: #F5F5F5;"|
:Transport of [[cholesterol]]→<br/>[[cholesterol]]
| style="padding: 5px 5px; background: #F5F5F5;"|
:Into mitochondria→<br/>[[Pregnenolone]]
|-
|-
|[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
|Increased:
* DOC
* 11-Deoxy-[[Cortisol]]
Decreased:
* [[Cortisol]]
* [[Corticosterone]]
* [[Aldosterone]]
|
* Low [[testosterone]] levels
|
* [[Hypertension]] and [[hypokalemia]]
* [[Virilization]]
|-
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
|Increased:
* [[DHEA]]
* [[17-hydroxypregnenolone]]
* [[Pregnenolone]]
Decreased:
* [[Cortisol]]
* [[Aldosterone]]
|
* Low [[testosterone]] levels
|
* Salt-wasting [[adrenal crisis]] in infancy


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |  
* Mild [[virilization]] of genetically female infants
'''  [[Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency|17α-hydroxylase CAH]]'''
* [[Undervirilization]] of genetically male infants, making it the only form of [[CAH]] which can cause [[ambiguous genitalia]] in both genetic sexes.
| style="padding: 5px 5px; background: #F5F5F5;"|
|-
:{{OMIM|202110}}
|[[Polycystic ovary syndrome ]]
| style="padding: 5px 5px; background: #F5F5F5;"|  
|
:P450c17
* High [[DHEAS]] and [[androstenedione]] levels
| style="padding: 5px 5px; background: #F5F5F5;"|
|
:10q24.3
* Low [[testosterone]] levels
| style="padding: 5px 5px; background: #F5F5F5;"|  
|
:[[pregnenolone]]→<br/>[[progesterone]]→<br/>17OH-pregnenolone→
* [[Polycystic ovaries]] in sonography
| style="padding: 5px 5px; background: #F5F5F5;"|  
* [[Obesity]]
:17OH-pregnenolone<br/>17OH-progesterone<br/>[[DHEA]]
* [[PCOS]] is the most common cause of [[hirsutism]] in women
* No evidence another diagnosis
|-
|[[Adrenal tumors]]
|
* Variable levels depends on [[tumor]] type
|
* Low [[testosterone]] level
|
* Older age
* Rapidly progressive symptoms
|-
|Ovarian [[virilizing]] tumor
|
* Variable levels depends on [[tumor]] type
|
* [[Testosterone]] is high
|
* Older age
* Rapidly progressive symptoms
|-
|[[Cushing's syndrome]]
|
* Increase [[cortisol]] & metabolites
* Variable other [[steroids]]
|
* Variable [[mineralocorticoid]] excess
|
* [[Cushingoid appearance]]
|-
|[[Hyperprolactinemia]]
|
* Normal levels of most of [[steroids]]
|
* Increased [[prolactin]]
|
* [[Infertility]]
* [[galactorrhea]]
|}
 
===Some types of congenital adrenal hyperplasia must be differentiated from diseases with [[primary amenorrhea]]:<ref name="pmid21147889">{{cite journal |vauthors=Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C |title=Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients |journal=J. Clin. Endocrinol. Metab. |volume=96 |issue=2 |pages=296–307 |year=2011 |pmid=21147889 |doi=10.1210/jc.2010-1024 |url=}}</ref><ref name="pmid2164530">{{cite journal |vauthors=Moreira AC, Leal AM, Castro M |title=Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency |journal=J. Clin. Endocrinol. Metab. |volume=71 |issue=1 |pages=86–91 |year=1990 |pmid=2164530 |doi=10.1210/jcem-71-1-86 |url=}}</ref><ref name="pmid999330">{{cite journal |vauthors=Heremans GF, Moolenaar AJ, van Gelderen HH |title=Female phenotype in a male child due to 17-alpha-hydroxylase deficiency |journal=Arch. Dis. Child. |volume=51 |issue=9 |pages=721–3 |year=1976 |pmid=999330 |pmc=1546244 |doi= |url=}}</ref><ref name="pmid226795">{{cite journal |vauthors=Biglieri EG |title=Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome |journal=J. Steroid Biochem. |volume=11 |issue=1B |pages=653–7 |year=1979 |pmid=226795 |doi= |url=}}</ref><ref name="pmid8929268">{{cite journal |vauthors=Saenger P |title=Turner's syndrome |journal=N. Engl. J. Med. |volume=335 |issue=23 |pages=1749–54 |year=1996 |pmid=8929268 |doi=10.1056/NEJM199612053352307 |url=}}</ref><ref name="pmid25813279">{{cite journal |vauthors=Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R |title=Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis |journal=Fertil. Steril. |volume=103 |issue=5 |pages=1297–304 |year=2015 |pmid=25813279 |doi=10.1016/j.fertnstert.2015.01.043 |url=}}</ref><ref name="pmid4432067">{{cite journal |vauthors=Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE |title=Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism |journal=Science |volume=186 |issue=4170 |pages=1213–5 |year=1974 |pmid=4432067 |doi= |url=}}</ref><ref name="pmid11344932">{{cite journal |vauthors=Schnitzer JJ, Donahoe PK |title=Surgical treatment of congenital adrenal hyperplasia |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=1 |pages=137–54 |year=2001 |pmid=11344932 |doi= |url=}}</ref>===


{| class="wikitable"
|-
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + | Disease
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + | Cause
! colspan="7" style="background:#4479BA; color: #FFFFFF;" + | Differentiating
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Findings
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Uterus
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Breast development
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Testosterone
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LH
! align="center" style="background:#4479BA; color: #FFFFFF;" + |FSH
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Karyotyping
|-
|-
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
|
* HSD3B2  [[gene]] [[mutation]]
|
* [[Undervirilization]] in 46,XY individuals due to a block in [[testosterone]] biosynthesis.
* Mild [[virilization]] in 46,XX individuals
| align="center" style="padding: 5px 5px; background: " |
Yes in [[female]]
| align="center" style="padding: 5px 5px; background: " |
Yes in [[female]]
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XY]] and [[XX]]
|-
|[[17-alpha-hydroxylase deficiency]]
|
* [[CYP17A1|CYP17A1 gene mutation]]
|
* Female [[external genitalia]]


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |  
* [[Primary amenorrhea]]
'''[[Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency|3β-HSD CAH]]'''
* [[Hypertension]]
| style="padding: 5px 5px; background: #F5F5F5;"|
* Absence of secondary [[sexual characteristics]]
:{{OMIM|201810}}
* Minimal [[body hair]]
| style="padding: 5px 5px; background: #F5F5F5;"|  
| align="center" style="padding: 5px 5px; background: " |
:3βHSD II
No
| style="padding: 5px 5px; background: #F5F5F5;"|
| align="center" style="padding: 5px 5px; background: " |
:1p13
No
| style="padding: 5px 5px; background: #F5F5F5;"|  
| align="center" style="padding: 5px 5px; background: " |
:[[Pregnenolone]]→<br/>17OH-pregnenolone→<br/>[[DHEA]]
| style="padding: 5px 5px; background: #F5F5F5;"|  
| align="center" style="padding: 5px 5px; background: " |
:[[Progesterone]]<br/>17OH-progesterone<br/>[[androstenedione]]
Normal
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[Gonadal dysgenesis]]
|
* Mutations in [[SRY]], FOG2/ZFPM2, and WNT1
|
* Female [[external genitalia]]
* Intact [[Mullerian ducts]]
* Streak [[gonads]]  
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[Testicular regression syndrome]]
|
* Loss of [[testicular]] function and tissue early in development
|
* Female phenotype with atrophic [[Mullerian ducts]].
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[LH receptor|LH receptor defects]]
|
* [[LH receptor]] [[gene]] [[mutation]] on [[chromosome 2]]
|
* Female [[external genitalia]]
* Lack a [[uterus]] and [[fallopian tubes]]
* [[Epididymis]] and [[vas deferens]] may be present
* Laboratory:
** Unresponsiveness to [[hCG]]
** Normal levels of [[testosterone]] precursors (produced in the [[adrenal glands]]).
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[5-alpha-reductase deficiency|5-alpha-reductase type 2 deficiency]]
|
* [[Autosomal recessive]]
|
* Female [[external genitalia or ambiguous]]
* Bilateral testes and normal [[testosterone]] formation


* Impaired external [[virilization]] during [[embryogenesis]]
* Defective conversion of [[testosterone]] to [[DHT]].
* [[Testosterone]]:[[DHT]] ratio is >10:1
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
Normal male range
| align="center" style="padding: 5px 5px; background: " |
High to normal
| align="center" style="padding: 5px 5px; background: " |
High to normal
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|-
|[[Androgen insensitivity syndrome]] 
|
* [[Androgen receptor]] defect
|
* Female [[external genitalia]]
* Resistant to [[testosterone]]
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Normal male range
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[Mullerian agenesis]]
|
* Mutations in ''[[WNT4]]''
|
* Normal female [[genitalia]]
* Normal [[breast]] development
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Normal [[female]] range
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XX]]
|-
|[[Ovarian insufficiency|Primary ovarian insufficiency]]
|
* [[Genetic defects]] such as [[turner syndrome]], [[fragile X syndrome]], some other chromosomal defects
|
* Normal [[female genitalia]]
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Normal female range
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XX]]
|-
|[[Hypogonadotropic hypogonadism]]
|
* Functional, sellar masses
|
* Normal [[female genitalia]],


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |  
* Delayed [[puberty]]
'''[[Congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency|11β-hydroxylase CAH]]'''
| align="center" style="padding: 5px 5px; background: " |
| style="padding: 5px 5px; background: #F5F5F5;"|
Yes
:{{OMIM|202010}}
| align="center" style="padding: 5px 5px; background: " |
| style="padding: 5px 5px; background: #F5F5F5;"|  
No
:P450c11β
| align="center" style="padding: 5px 5px; background: " |
| style="padding: 5px 5px; background: #F5F5F5;"|
Normal female range
:8q21-22
| align="center" style="padding: 5px 5px; background: " |
| style="padding: 5px 5px; background: #F5F5F5;"|  
Low
:11-deoxycortisol→<br/>DOC→
| align="center" style="padding: 5px 5px; background: " |
| style="padding: 5px 5px; background: #F5F5F5;"|  
Normal
:[[Cortisol]]<br/>[[Corticosterone]]
| align="center" style="padding: 5px 5px; background: " |
[[XX]]
|-
| align="center" style="padding: 5px 5px; background: " |
[[Turner syndrome]]
|
* Chromosomal
|
* Normal female [[external genitalia]]
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Normal [[female]] range
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[Turner syndrome|45 XO]]
|}
|}


==Pathophysiology==
=== [[17 alpha-hydroxylase deficiency]] and [[11β-hydroxylase deficiency]] can cause low reninemic [[hypertension]] and should be differentiate from other causes of [[pseudohyperaldosteronism]] (low renin): ===
{| class="wikitable"
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Pseudohyperaldosteronism causes
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical features
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Labratory
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Treatment
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Elevated mineralocorticoid
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Renin
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Aldosterone
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
|-
| rowspan="9" |Endogenous causes
|[[17 alpha-hydroxylase deficiency]]
|Mutations in the [[CYP17A1]] gene
|
* [[Ambiguous genitalia]] in male
* [[Hypertension]]


==Causes==
* [[Primary amenorrhea]]


==Differentiating {{PAGENAME}} from Other Diseases==
* Absence of [[secondary sexual characteristics]]
 
* Minimal [[body hair]]
| rowspan="2" |[[Deoxycorticosterone]] ([[Deoxycorticosterone|DOC]])
| rowspan="2" |↓
| rowspan="2" |↓
|[[Cortisol]] ↓
| rowspan="2" |[[Corticosteroids]]
|-
|[[11β-hydroxylase deficiency]]
|Mutations in the [[CYP11B1]] gene
|
* [[Ambiguous genitalia]] in female
 
* [[Hypertension]] and [[hypokalemia]]
* [[Virilization]]
|[[Cortisol]] ↓
|-
|Apparent mineralocorticoid excess syndrome (AME)
|Genetic or acquired defect of 11-HSD gene
* [[Cortisone]] decreases and [[cortisol]] accumulates and binds to [[aldosterone]] receptors
|
* Severe juvenile [[hypertension]]
* [[Hypercalciuria]], [[nephrocalcinosis]], [[polyuria]] (due to [[hypokalemia]]-induced [[nephrogenic diabetes insipidus]])
* [[Renal failure]]
|[[Cortisol]] has [[mineralocorticoid]] effects
|↓
|↓
|Urinary free [[cortisone]] ↓↓
|[[Dexamethasone]] and/or [[mineralocorticoid]] blockers
|-
|[[Liddle's syndrome|Liddle’s syndrome]] (Pseudohyperaldosteronism type 1)
|Mutation of the epithelial [[sodium]] channels ([[ENaC]]) [[gene]] in the distal [[renal tubules]]
|
* [[Hypertension]]
 
* [[Hypokalemia]]
|No extra [[mineralocorticoid]] presents, and mutations in [[Sodium|Na]] channels mimic [[aldosterone]] mechanism
|↓
|↓
|[[Cortisol]] ↓
|[[Amiloride]] or [[triamterene]]
|-
|[[Cushing’s syndrome]]
|
* The main pathogenetic mechanism is linked to the excess
of [[cortisol]] which saturates 11-HSD2 activity,
* This allows [[cortisol]] to bind [[mineralocorticoid receptor]]
|Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
* Proximal [[muscle weakness]]
* A [[round face]] often referred to as a "[[moon face]]"
* Excess [[sweating]]
* [[Headache]]
|[[Cortisol]] has [[mineralocorticoid]] effects
|↓
|
* ↓ if excess [[cortisol]] saturates 11-HSD2 enzyme activity


==Epidemiology and Demographics==
* ↑ in direct activation of [[renin]] [[angiotensin]] system activation by [[glucocorticoids]]
|Urinary free [[cortisol]] markedly ↑↑
|
* [[Pasireotide]], [[Cabergoline]], [[Ketoconazole]], and [[Metyrapone]]


==Risk Factors==
* Adrenalectomy
|-
|Insensitivity to [[glucocorticoids]] (Chrousos syndrome)
|Mutations in [[glucocorticoid receptor]] (GR) gene
|
* [[Hypertension]]


==Screening==
* Adrenal [[hyperandrogenism]]
|[[Deoxycorticosterone]] ([[Deoxycorticosterone|DOC]])
|↓
|↓
|[[Cortisol]]
|[[Dexamethasone]]
|-
|[[Cortisol]]-secreting adrenocortical [[carcinoma]]
|Multifactorial
|
Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
* Proximal [[muscle weakness]]
* A [[round face]] often referred to as a "[[moon face]]"
* Excess [[sweating]]
* [[Headache]]
|[[Cortisol]] has [[mineralocorticoid]] effects
|↓
|
* ↓ if excess [[cortisol]] saturates 11-HSD2 enzyme activity


==Natural History, Complications, and Prognosis==
* ↑ in direct activation of [[renin]] [[angiotensin]] system activation by [[glucocorticoids]]
|Urinary free [[cortisol]] markedly ↑↑
|[[Surgery]]
|-
|Geller’s syndrome
|[[Mutation]] of [[mineralocorticoid]] (MR) receptor that alters its specificity and allows [[progesterone]] to bind MR
|Severe [[hypertension]] particularly during [[pregnancy]]
|[[Progesterone]] has [[mineralocorticoid]] effects
|↓
|↓
| -
|[[mineralocorticoid]] blockers
|-
|Gordon’s syndrome (Pseudohypoaldosteronism type 2)
|Mutations of at least four genes have been identified, including WNK1 and WNK4
|
* [[Hypertension]]


==Diagnosis==
* [[Hyperkalemia]]
===Diagnostic Criteria===


===History and Symptoms===
* Normal renal function
|No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule
|↓
|Normal
|Hyperkalemia
|thiazide diuretics and/or dietary sodium restriction
|-
| rowspan="4" |Exogenous causes
|Corticosteroids with mineralocorticoid activity
|Fludrocortisone or fluoroprednisolone can mimic the action of aldosterone,
|
* [[Hypertension]]


===Physical Examination===
* [[Hypokalemia]]
|Medications such as fludrocortisone
|↓
|↓
| -
|Change the treatment
|-
|Licorice ingestion
|[[Glycyrrhetinic acid]] that binds [[mineralocorticoid]] receptor and blocks 11-HSD2 at the level of classical target tissues of [[aldosterone]]
|
* [[Hypertension]]


===Laboratory Findings===
* [[Hypokalemia]]
|<nowiki>-</nowiki>
|↓
|↓
|Urinary free cortisol Moderate ↑
|Discontinue licorice
|-
|Grapefruit
|High assumption of naringenin, a component of grapefruit, can also block 11-HSD
|
* [[Hypertension]]
| -
|↓
|↓
| -
|Discontinue grapefruit
|-
|[[Estrogens]]
|[[Estrogens]] can retain [[sodium]] and water by different mechanisms, causing:
* Increased blood pressure values and suppressing the [[renin]] [[aldosterone]] system, on the other side inducing secondary hyperaldosteronism due to the stimulation of the synthesis of [[angiotensinogen]]
|
* [[Hypertension]]


===Imaging Findings===
* [[Headache]]
* [[Edema]]
* [[Weight gain]]
|<nowiki>-</nowiki>
|↓
|↓
| -
|Discontinue [[estrogens]]
|}


===Other Diagnostic Studies===
==== CAH must be differentiated from other causes of irregular menses and [[hirsutism]]: ====
{| class="wikitable"
!Disease
!Differentiating Features
|-
|[[Pregnancy]]
|
* Pregnancy always should be excluded in a patient with a history of [[amenorrhea]]


==Treatment==
* Features include amenorrhea or [[oligomenorrhea]], abnormal [[uterine bleeding]], [[Nausea and vomiting|nausea/vomiting]], cravings, [[weight gain]] (although not in the early stages and not if vomiting), [[polyuria]], [[abdominal cramps]] and [[constipation]], [[fatigue]], [[dizziness]]/[[lightheadedness]], and [[Hyperpigmentation|increased pigmentation]] (moles, [[nipples]])
===Medical Therapy===


===Surgery===
* [[Uterus|Uterine]] enlargement is detectable on [[abdominal examination]] at approximately 14 weeks of [[gestation]]


===Prevention===
* [[Ectopic pregnancy]] may cause oligomenorrhea, amenorrhea, or abnormal uterine bleeding with [[abdominal pain]] and sometimes subtle or absent physical symptoms and signs of [[pregnancy]]
|-
|Hypothalamic amenorrhea
|
* Diagnosis of exclusion
* Seen in athletes, people on crash diets, patients with significant systemic illness, and those experiencing undue [[stress]] or [[anxiety]]
* Predisposing features are as follows [[weight loss]], particularly if features of [[anorexia nervosa]] are present or the [[BMI]] is <19 kg/m2
* Recent administration of depot [[Medroxyprogesterone acetate|medroxyprogesterone]], which may suppress [[ovarian]] activity for 6 months to a year
* Use of [[dopamine agonists]] (eg, antidepressants) and major [[tranquilizers]]
* [[Hyperthyroidism]]
* In patients with weight loss related to anorexia nervosa, fine hair growth ([[lanugo]]) may occur all over the body, but it differs from [[hirsutism]] in its fineness and wide distribution
|-
|[[Primary amenorrhea]]
|
* Causes include [[reproductive system]] abnormalities, [[chromosomal]] abnormalities, or [[delayed puberty]]
* If [[secondary sexual characteristics]] are present, an [[anatomic]] abnormality (eg, [[imperforate hymen]], which is rare) should be considered
* If secondary sexual characteristics are absent, a chromosomal abnormality (eg, [[Turner syndrome]] ) or [[delayed puberty]] should be considered
|-
|[[Cushing's syndrome|Cushing syndrome]]
|
* [[Cushing syndrome]] is due to excessive [[glucocorticoid]] secretion from the [[adrenal glands]], either primarily or secondary to stimulation from [[Pituitary gland|pituitary]] or ectopic hormones; can also be caused by exogenous [[steroid]] use


==Reference==
* Features include [[hypertension]], [[weight gain]] (central distribution), [[acne]], and abdominal striae Patients have [[Hyponatremia|low plasma sodium levels]] and elevated plasma cortisol levels on [[dexamethasone]] suppression testing
{{Reflist|2}}
|-
|[[Hyperprolactinemia]]
|
* Mild [[hyperprolactinemia]] may occur as part of [[PCOS]]-related hormonal dysfunction


[[Category:Endocrinology]]
* Other causes include [[stress]], [[lactation]], and use of [[dopamine antagonists]]
* A [[prolactinoma]] of the [[pituitary gland]] is an uncommon cause and should be suspected if [[prolactin]] levels are very high (>200 ng/mL)
* Physical examination findings are usually normal
* As in patients with PCOS, hyperprolactinemia may be associated with mild [[galactorrhea]] and [[oligomenorrhea]] or [[amenorrhea]]; however, galactorrhea also can occur with [[nipple]] stimulation and/or [[stress]] when prolactin levels are within normal ranges
* A large [[prolactinoma]] may cause [[headaches]] and [[visual field]] disturbance due to pressure on the [[optic chiasm]], classically a gradually increasing bi-temporal hemianopsia
|-
|Ovarian or adrenal tumor
|
* Benign [[Ovarian tumor|ovarian tumors]] and ovarian cancer are rare causes of excessive [[androgen]] secretion; [[adrenocortical]] [[tumors]] also can increase the production of [[sex hormones]]
* [[Abdominal swelling]] or [[mass]], [[abdominal pain]] due to fluid leakage or [[torsion]], [[dyspareunia]], abdominal [[ascites]], and features of [[metastatic]] disease may be present
* Features of androgenization include [[hirsutism]], [[weight gain]], [[oligomenorrhea]] or [[amenorrhea]], [[acne]], [[clitoral hypertrophy]], deepening of the voice, and high [[Androgen|serum androgen]] (eg, [[testosterone]], other androgens) levels
* In patients with an androgen-secreting tumor, serum testosterone is not suppressed by [[dexamethasone]]
|-
|[[Congenital adrenal hyperplasia]]
|
* Congenital adrenal hyperplasia is a rare [[genetic]] condition resulting from 21-hydroxylase deficiency
* The late-onset form presents at or around menarche Patients have features of androgenization and [[subfertility]]
* Affects approximately 1% of hirsute patients More common in Ashkenazi Jews (19%), inhabitants of the former Yugoslavia (12%), and Italians (6%)
* Associated with high levels of [[17-hydroxyprogesterone]]
* A short [[adrenocorticotropic hormone]] stimulation test with measurement of serum17-hydroxyprogesterone confirms the diagnostic assays of a variety of androgenic hormones help define other rare adrenal enzyme deficiencies, which present similarly to [[21-hydroxylase deficiency]]
|-
|Anabolic steroid abuse
|
* [[Anabolic steroid|Anabolic steroids]] are synthetic hormones that imitate the actions of [[testosterone]] by increasing [[muscle]] bulk and strength
* Should be considered if the patient is a serious sportswoman or bodybuilder
* Features include [[virilization]] (including [[acne]] and [[hirsutism]]), often increased muscle bulk in male pattern, [[oligomenorrhea]] or [[amenorrhea]], [[clitoromegaly]], [[gastritis]], [[hepatomegaly]], [[alopecia]], and aggression
* Altered [[liver function test]] results are seen
|-
|[[Hirsutism]]
|
* [[Hirsutism]] is excessive facial and body hair, usually coarse and in a male pattern of distribution
* Approximately 10% of women report unwanted facial hair
* There is often a family history and typically some Mediterranean or Middle Eastern ancestry
* May also result from use of certain [[medications]], both [[androgens]], and others including [[danazol]], [[glucocorticoids]], [[cyclosporine]], and [[phenytoin]]
* [[Menstrual cycle|Menstrual]] history is normal
* When the cause is [[Genetics|genetic]], the excessive hair, especially on the face (upper lip), is present throughout adulthood, and there is no virilization
* When secondary to medications, the excessive hair is of new onset, and other features of virilization, such as [[acne]] and deepened voice, may be present
|}


{{WS}}
==References==
{{WH}}
{{reflist|2}}

Latest revision as of 15:57, 23 April 2018

This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on 21-hydroxylase deficiency, 17 alpha-hydroxylase deficiency, 11β-hydroxylase deficiency, 3 beta-hydroxysteroid dehydrogenase deficiency, cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia.

Adrenal insufficiency
Adrenal gland

Congenital adrenal hyperplasia main page

Overview

Classification

21-hydroxylase deficiency
11β-hydroxylase deficiency
17 alpha-hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Cytochrome P450-oxidoreductase (POR) deficiency (ORD)
Lipoid congenital adrenal hyperplasia

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Synonyms and keywords: Congenital adrenal hyperplasia; CAH; Adrenal hyperplasia.

Overview

Congenital adrenal hyperplasia consists of several disorders resulting from defective enzymes and proteins involved in steroid and cortisol synthesis pathways. Defects in steroid biosynthesis are caused by several genetic mutations and may lead to delayed puberty, precocious puberty or ambiguous genitalia in specific disorders. The decrease in cortisol level leads to the release of the inhibitory feedback on corticotropin (ACTH) production. The high ACTH level causes increase cortisol precursors and overproduction of other hormones. The most common cause of congenital adrenal hyperplasia is a 21-hydroxylase deficiency, which accounts for more than 95% of cases. Other causes include 17 alpha-hydroxylase deficiency, 11β-hydroxylase deficiency, 3 beta-hydroxysteroid dehydrogenase deficiency, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), and congenital lipoid adrenal hyperplasia.

Classification

Congenital adrenal hyperplasia (CAH) is classified into seven types based on the genetic causes that lead to hyperplasia and hormonal imbalance. CAH is hyperplasia of different layer of Adrenal cortex. Within the adrenal cortex, there are three layers named zones; each of them has a distinct cell type and secrete specific hormones.

Adrenal cortex zones based on the hormonal synthesis ability and location:

Adrenal cortex zones - By Jpogi - https://commons.wikimedia.org/wiki/File:Adrenal_gland_%28cortex%29.JPG, CC0, https://commons.wikimedia.org/w/index.php?curid=37838551

Impairment of each pathway and enzyme may lead to a specific subtype of congenital adrenal hyperplasia include:

Adrenal steroid synthesis pathways in adrenal cortex and related enzymes

Adrenal steroid synthesis pathways in adrenal cortex and related enzymes [1]

Summary and important Characteristics of the different congenital adrenal hyperplasia subtypes: [2][3][4]

Disease History and symptoms Laboratory findings Defective gene
Blood pressure Genitalia Cortisol Aldosterone Androgens Estrogens Increased hormone precursors Potassium levels
21-hydroxylase deficiency Classic type, salt-wasting ↓↓ Relatively low

CYP21A1 and CYP21A2 gene

Classic type, non-salt-wasting Normal
  • Male: normal or scrotal pigmentation and large phallus
Relatively low Normal CYP21A1 and CYP21A2 gene
Non-classic type Normal Normal Normal Relatively low Normal

CYP21A1 and CYP21A2 gene

17-α hydroxylase deficiency Normal corticosterone

Normal cortisol

CYP17A1
11-β hydroxylase deficiency
  • Male: Normal or scrotal pigmentation and large phallus
Relatively low CYP11B1
3 beta-hydroxysteroid dehydrogenase deficiency Male:↓

Female:↑

HSD3B2
Cytochrome P450-oxidoreductase (POR) deficiency (ORD) Normal Normal Normal Mutations in the flavoprotein co-factor of the enzymes CYP17A1, CYP21A2, and CYP19A1 (aromatase).
Congenital lipoid adrenal hyperplasia None of precursors increased Gene mutations on chromosome 8, codes for a protein called steroid acute regulatory protein (StAR)

Differential Diagnosis

Congenital adrenal hyperplasia can present with different symptoms such as:

Differential diagnosis for each of these symptoms are described in below tables.

Congenital adrenal hyperplasia must be differentiated from diseases that cause ambiguous genitalia:[5][6]

Disease Steroid status Important clinical findings
Increased Decreased
Classic type of 21-hydroxylase deficiency
11-β hydroxylase deficiency
17-α hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Gestational hyperandrogenism

Congenital adrenal hyperplasia must be differentiated from diseases that cause virilization and hirsutism in female:[7][6][8]

Disease Steroid status Other laboratory Important clinical findings
Non-classic type of 21-hydroxylase deficiency Increased:
  • No symptoms in infancy and male
11-β hydroxylase deficiency Increased:

Decreased:

3 beta-hydroxysteroid dehydrogenase deficiency Increased:

Decreased:

Polycystic ovary syndrome
Adrenal tumors
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Ovarian virilizing tumor
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Cushing's syndrome
Hyperprolactinemia

Some types of congenital adrenal hyperplasia must be differentiated from diseases with primary amenorrhea:[9][2][3][4][10][11][12][13]

Disease Cause Differentiating
Findings Uterus Breast development Testosterone LH FSH Karyotyping
3 beta-hydroxysteroid dehydrogenase deficiency

Yes in female

Yes in female

Normal

Normal

XY and XX

17-alpha-hydroxylase deficiency

No

No

Normal

Normal

XY

Gonadal dysgenesis
  • Mutations in SRY, FOG2/ZFPM2, and WNT1

Yes

Yes

XY

Testicular regression syndrome
  • Loss of testicular function and tissue early in development

No

No

XY

LH receptor defects

No

No

XY

5-alpha-reductase type 2 deficiency

No

No

Normal male range

High to normal

High to normal

XY

Androgen insensitivity syndrome 

No

Yes

Normal male range

Normal

Normal

XY

Mullerian agenesis

No

Yes

Normal female range

Normal

Normal

XX

Primary ovarian insufficiency

Yes

Yes

Normal female range

XX

Hypogonadotropic hypogonadism
  • Functional, sellar masses

Yes

No

Normal female range

Low

Normal

XX

Turner syndrome

  • Chromosomal

Yes

Yes

Normal female range

45 XO

17 alpha-hydroxylase deficiency and 11β-hydroxylase deficiency can cause low reninemic hypertension and should be differentiate from other causes of pseudohyperaldosteronism (low renin):

Pseudohyperaldosteronism causes Disease Etiology Clinical features Labratory Treatment
Elevated mineralocorticoid Renin Aldosterone Other
Endogenous causes 17 alpha-hydroxylase deficiency Mutations in the CYP17A1 gene Deoxycorticosterone (DOC) Cortisol Corticosteroids
11β-hydroxylase deficiency Mutations in the CYP11B1 gene Cortisol
Apparent mineralocorticoid excess syndrome (AME) Genetic or acquired defect of 11-HSD gene Cortisol has mineralocorticoid effects Urinary free cortisone ↓↓ Dexamethasone and/or mineralocorticoid blockers
Liddle’s syndrome (Pseudohyperaldosteronism type 1) Mutation of the epithelial sodium channels (ENaC) gene in the distal renal tubules No extra mineralocorticoid presents, and mutations in Na channels mimic aldosterone mechanism Cortisol Amiloride or triamterene
Cushing’s syndrome
  • The main pathogenetic mechanism is linked to the excess

of cortisol which saturates 11-HSD2 activity,

Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity) Cortisol has mineralocorticoid effects
  • ↓ if excess cortisol saturates 11-HSD2 enzyme activity
Urinary free cortisol markedly ↑↑
  • Adrenalectomy
Insensitivity to glucocorticoids (Chrousos syndrome) Mutations in glucocorticoid receptor (GR) gene Deoxycorticosterone (DOC) Cortisol Dexamethasone
Cortisol-secreting adrenocortical carcinoma Multifactorial

Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity)

Cortisol has mineralocorticoid effects
  • ↓ if excess cortisol saturates 11-HSD2 enzyme activity
Urinary free cortisol markedly ↑↑ Surgery
Geller’s syndrome Mutation of mineralocorticoid (MR) receptor that alters its specificity and allows progesterone to bind MR Severe hypertension particularly during pregnancy Progesterone has mineralocorticoid effects - mineralocorticoid blockers
Gordon’s syndrome (Pseudohypoaldosteronism type 2) Mutations of at least four genes have been identified, including WNK1 and WNK4
  • Normal renal function
No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule Normal Hyperkalemia thiazide diuretics and/or dietary sodium restriction
Exogenous causes Corticosteroids with mineralocorticoid activity Fludrocortisone or fluoroprednisolone can mimic the action of aldosterone, Medications such as fludrocortisone - Change the treatment
Licorice ingestion Glycyrrhetinic acid that binds mineralocorticoid receptor and blocks 11-HSD2 at the level of classical target tissues of aldosterone - Urinary free cortisol Moderate ↑ Discontinue licorice
Grapefruit High assumption of naringenin, a component of grapefruit, can also block 11-HSD - - Discontinue grapefruit
Estrogens Estrogens can retain sodium and water by different mechanisms, causing:
  • Increased blood pressure values and suppressing the renin aldosterone system, on the other side inducing secondary hyperaldosteronism due to the stimulation of the synthesis of angiotensinogen
- - Discontinue estrogens

CAH must be differentiated from other causes of irregular menses and hirsutism:

Disease Differentiating Features
Pregnancy
  • Pregnancy always should be excluded in a patient with a history of amenorrhea
Hypothalamic amenorrhea
  • Diagnosis of exclusion
  • Seen in athletes, people on crash diets, patients with significant systemic illness, and those experiencing undue stress or anxiety
  • Predisposing features are as follows weight loss, particularly if features of anorexia nervosa are present or the BMI is <19 kg/m2
  • Recent administration of depot medroxyprogesterone, which may suppress ovarian activity for 6 months to a year
  • Use of dopamine agonists (eg, antidepressants) and major tranquilizers
  • Hyperthyroidism
  • In patients with weight loss related to anorexia nervosa, fine hair growth (lanugo) may occur all over the body, but it differs from hirsutism in its fineness and wide distribution
Primary amenorrhea
Cushing syndrome
Hyperprolactinemia
Ovarian or adrenal tumor
Congenital adrenal hyperplasia
  • Congenital adrenal hyperplasia is a rare genetic condition resulting from 21-hydroxylase deficiency
  • The late-onset form presents at or around menarche Patients have features of androgenization and subfertility
  • Affects approximately 1% of hirsute patients More common in Ashkenazi Jews (19%), inhabitants of the former Yugoslavia (12%), and Italians (6%)
  • Associated with high levels of 17-hydroxyprogesterone
  • A short adrenocorticotropic hormone stimulation test with measurement of serum17-hydroxyprogesterone confirms the diagnostic assays of a variety of androgenic hormones help define other rare adrenal enzyme deficiencies, which present similarly to 21-hydroxylase deficiency
Anabolic steroid abuse
Hirsutism
  • Hirsutism is excessive facial and body hair, usually coarse and in a male pattern of distribution
  • Approximately 10% of women report unwanted facial hair
  • There is often a family history and typically some Mediterranean or Middle Eastern ancestry
  • May also result from use of certain medications, both androgens, and others including danazol, glucocorticoids, cyclosporine, and phenytoin
  • Menstrual history is normal
  • When the cause is genetic, the excessive hair, especially on the face (upper lip), is present throughout adulthood, and there is no virilization
  • When secondary to medications, the excessive hair is of new onset, and other features of virilization, such as acne and deepened voice, may be present

References

  1. "File:Adrenal Steroids Pathways.svg - Wikimedia Commons".
  2. 2.0 2.1 Moreira AC, Leal AM, Castro M (1990). "Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency". J. Clin. Endocrinol. Metab. 71 (1): 86–91. doi:10.1210/jcem-71-1-86. PMID 2164530.
  3. 3.0 3.1 Heremans GF, Moolenaar AJ, van Gelderen HH (1976). "Female phenotype in a male child due to 17-alpha-hydroxylase deficiency". Arch. Dis. Child. 51 (9): 721–3. PMC 1546244. PMID 999330.
  4. 4.0 4.1 Biglieri EG (1979). "Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome". J. Steroid Biochem. 11 (1B): 653–7. PMID 226795.
  5. Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
  6. 6.0 6.1 White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
  7. Hohl A, Ronsoni MF, Oliveira M (2014). "Hirsutism: diagnosis and treatment". Arq Bras Endocrinol Metabol. 58 (2): 97–107. PMID 24830586. Vancouver style error: initials (help)
  8. Melmed, Shlomo (2016). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.=
  9. Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C (2011). "Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients". J. Clin. Endocrinol. Metab. 96 (2): 296–307. doi:10.1210/jc.2010-1024. PMID 21147889.
  10. Saenger P (1996). "Turner's syndrome". N. Engl. J. Med. 335 (23): 1749–54. doi:10.1056/NEJM199612053352307. PMID 8929268.
  11. Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R (2015). "Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis". Fertil. Steril. 103 (5): 1297–304. doi:10.1016/j.fertnstert.2015.01.043. PMID 25813279.
  12. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170): 1213–5. PMID 4432067.
  13. Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.